JP2018510131A - Ｒｏｒｃ２のスルホンアミド置換インドールモジュレーターおよびその使用方法 - Google Patents

Ｒｏｒｃ２のスルホンアミド置換インドールモジュレーターおよびその使用方法 Download PDF

Info

Publication number
JP2018510131A
JP2018510131A JP2017539457A JP2017539457A JP2018510131A JP 2018510131 A JP2018510131 A JP 2018510131A JP 2017539457 A JP2017539457 A JP 2017539457A JP 2017539457 A JP2017539457 A JP 2017539457A JP 2018510131 A JP2018510131 A JP 2018510131A
Authority
JP
Japan
Prior art keywords
juvenile
och
acid
compound
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2017539457A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018510131A5 (enExample
Inventor
エドワード シュヌーテ マーク
エドワード シュヌーテ マーク
クリストファー フリック アンドリュー
クリストファー フリック アンドリュー
ジョーンズ ピーター
ジョーンズ ピーター
カイラ ニールー
カイラ ニールー
リチャード メンテ スコット
リチャード メンテ スコット
デイヴィッド ターズペック ジョン
デイヴィッド ターズペック ジョン
エル． ヴァズケズ マイケル
エル． ヴァズケズ マイケル
シン リー
シン リー
チャン リーイン
チャン リーイン
マティアス ヴェンネルスタール ゴラン
マティアス ヴェンネルスタール ゴラン
ザマラツキ エドゥアルド
ザマラツキ エドゥアルド
Original Assignee
ファイザー・インク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファイザー・インク filed Critical ファイザー・インク
Publication of JP2018510131A publication Critical patent/JP2018510131A/ja
Publication of JP2018510131A5 publication Critical patent/JP2018510131A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
  • Furan Compounds (AREA)
JP2017539457A 2015-01-30 2016-01-29 Ｒｏｒｃ２のスルホンアミド置換インドールモジュレーターおよびその使用方法 Ceased JP2018510131A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562110060P 2015-01-30 2015-01-30
US62/110,060 2015-01-30
US201562267350P 2015-12-15 2015-12-15
US62/267,350 2015-12-15
PCT/IB2016/050477 WO2016120850A1 (en) 2015-01-30 2016-01-29 Sulfonamide-subsituted indole modulators of rorc2 and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2018510131A true JP2018510131A (ja) 2018-04-12
JP2018510131A5 JP2018510131A5 (enExample) 2019-06-20

Family

ID=55405379

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017539457A Ceased JP2018510131A (ja) 2015-01-30 2016-01-29 Ｒｏｒｃ２のスルホンアミド置換インドールモジュレーターおよびその使用方法

Country Status (5)

Country Link
US (1) US10385036B2 (enExample)
EP (1) EP3250561A1 (enExample)
JP (1) JP2018510131A (enExample)
CA (1) CA2975157C (enExample)
WO (1) WO2016120850A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10336748B2 (en) 2015-01-30 2019-07-02 Pfizer Inc. Methyoxy-substituted pyrrolopyridine modulators of RORC2 and methods of use thereof
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
GB201709456D0 (en) 2017-06-14 2017-07-26 Ucb Biopharma Sprl Therapeutic agents
KR102037494B1 (ko) 2017-12-11 2019-10-28 씨제이헬스케어 주식회사 광학활성을 갖는 피페리딘 유도체의 중간체 및 이의 제조방법
KR20190120112A (ko) 2019-10-08 2019-10-23 씨제이헬스케어 주식회사 광학활성을 갖는 피페리딘 유도체의 중간체 및 이의 제조방법
CN115322105A (zh) * 2021-05-11 2022-11-11 江苏润安制药有限公司 一种合成艾拉莫德关键中间体的方法
CN116135839A (zh) * 2021-11-18 2023-05-19 江苏润安制药有限公司 一种阿齐沙坦关键中间体的制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2691630A1 (fr) * 1992-05-28 1993-12-03 Glaxo Lab Sa Composition pharmaceutique, en particulier pour l'administration orale, contenant, comme ingrédient actif, un agoniste sélectif des récepteurs de type 5HT1.
JP2004526699A (ja) * 2001-01-30 2004-09-02 イーライ・リリー・アンド・カンパニー ５−ｈｔ６受容体の拮抗薬としてのベンゼンスルホン酸インドール−５−イルエステル類
WO2014026329A1 (en) * 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. N-alkylated indole and indazole compounds as rorgammat inhibitors and uses thereof
WO2014026328A1 (en) * 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. 3-cyclohexenyl substituted indole and indazole compounds as rorgammat inhibitors and uses thereof
WO2014026330A1 (en) * 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4742057A (en) 1985-12-05 1988-05-03 Fujisawa Pharmaceutical Co., Ltd. Antiallergic thiazole compounds
US5962473A (en) 1996-08-16 1999-10-05 Eli Lilly And Company Methods of treating or ameliorating the symptoms of common cold or allergic rhinitis with serotonin 5-HT1F
EP1003738B1 (en) 1997-08-09 2003-11-19 SmithKline Beecham plc Bicyclic compounds as ligands for 5-ht1 receptors
AU4425399A (en) 1998-06-08 1999-12-30 Advanced Medicine, Inc. Novel therapeutic agents that modulate 5-ht receptors
CN103649070B (zh) 2011-07-08 2016-05-18 先正达参股股份有限公司 用于制备硫杂环丁胺的方法
CA2919783C (en) 2013-08-02 2018-02-06 Pfizer Inc. Heterobicycloaryl rorc2 inhibitors and methods of use thereof
MA40759A (fr) 2014-09-26 2017-08-01 Pfizer Modulateurs de rorc2 de type pyrrolopyridine substitué par un méthyle et trifluorométhyle et leurs procédés d'utilisation
US10336748B2 (en) 2015-01-30 2019-07-02 Pfizer Inc. Methyoxy-substituted pyrrolopyridine modulators of RORC2 and methods of use thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2691630A1 (fr) * 1992-05-28 1993-12-03 Glaxo Lab Sa Composition pharmaceutique, en particulier pour l'administration orale, contenant, comme ingrédient actif, un agoniste sélectif des récepteurs de type 5HT1.
JP2004526699A (ja) * 2001-01-30 2004-09-02 イーライ・リリー・アンド・カンパニー ５−ｈｔ６受容体の拮抗薬としてのベンゼンスルホン酸インドール−５−イルエステル類
WO2014026329A1 (en) * 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. N-alkylated indole and indazole compounds as rorgammat inhibitors and uses thereof
WO2014026328A1 (en) * 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. 3-cyclohexenyl substituted indole and indazole compounds as rorgammat inhibitors and uses thereof
WO2014026330A1 (en) * 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LOPEZ-RODRIGUEZ, M. ET AL., JOURNAL OF MEDICINAL CHEMISTRY, vol. 48, JPN6019042472, 2005, pages 4216 - 4219, ISSN: 0004144853 *

Also Published As

Publication number Publication date
WO2016120850A9 (en) 2017-07-20
US10385036B2 (en) 2019-08-20
WO2016120850A1 (en) 2016-08-04
CA2975157C (en) 2019-09-17
CA2975157A1 (en) 2016-08-04
US20180273504A1 (en) 2018-09-27
EP3250561A1 (en) 2017-12-06

Similar Documents

Publication Publication Date Title
JP6224870B2 (ja) Ｒｏｒｃ２のメチルおよびトリフルオロメチル置換ピロロピリジンモジュレーターならびにその使用方法
US10385036B2 (en) Sulfonamide-substituted indole modulators of RORC2 and methods of use thereof
JP6224832B2 (ja) Ｒｏｒｃ２阻害薬およびその使用方法
US10336748B2 (en) Methyoxy-substituted pyrrolopyridine modulators of RORC2 and methods of use thereof
TW201028395A (en) Biologically active amides
HK1234388A1 (en) Methyl-and trifluoromethyl-substituted pyrrolopyridine modulators of rorc2 an methods of use thereof
HK1219093B (en) Heterobicycloaryl rorc2 inhibitors and methods of use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20181207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190122

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190306

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190306

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20191017

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191218

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200609

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20201117